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1. INTRODUCTION {#cas14167-sec-0001}
===============

Philadelphia chromosome (Ph) is the most common cytogenetic abnormality and is associated with dismal outcomes in adult acute lymphoblastic leukemia (ALL).[1](#cas14167-bib-0001){ref-type="ref"}, [2](#cas14167-bib-0002){ref-type="ref"} Introduction of tyrosine kinase inhibitor (TKI) has dramatically improved the survival outcomes in patients with Ph+ ALL.[3](#cas14167-bib-0003){ref-type="ref"}, [4](#cas14167-bib-0004){ref-type="ref"}, [5](#cas14167-bib-0005){ref-type="ref"}, [6](#cas14167-bib-0006){ref-type="ref"} However, relapse is the major problem in patients without allogeneic hematopoietic stem cell transplantation (HSCT) as a result of a high frequency of BCR‐ABL1 kinase domain mutations.[7](#cas14167-bib-0007){ref-type="ref"}, [8](#cas14167-bib-0008){ref-type="ref"}, [9](#cas14167-bib-0009){ref-type="ref"} Although allogenic HSCT might not be needed in patients with an early molecular response, which is achieved more frequently with second‐ or third‐generation TKI, the long‐term outcome is uncertain.[10](#cas14167-bib-0010){ref-type="ref"}, [11](#cas14167-bib-0011){ref-type="ref"}, [12](#cas14167-bib-0012){ref-type="ref"} Therefore, allogeneic HSCT is the preferred curative approach for Ph+ ALL in current clinical practice.[13](#cas14167-bib-0013){ref-type="ref"}, [14](#cas14167-bib-0014){ref-type="ref"}

Development of the ability to detect minimal residual disease (MRD) far below the level of 5% blast cells has changed the landscape of risk stratification over the last decade.[11](#cas14167-bib-0011){ref-type="ref"}, [15](#cas14167-bib-0015){ref-type="ref"}, [16](#cas14167-bib-0016){ref-type="ref"}, [17](#cas14167-bib-0017){ref-type="ref"} Several studies have shown that chemotherapy combined with TKI, which gives a higher complete remission (CR) rate and further MRD reduction, enables allogenic HSCT in a larger proportion of patients.[18](#cas14167-bib-0018){ref-type="ref"} Despite the evident benefit of giving TKI before allogenic HSCT, available data regarding the post‐transplant use of TKI are limited.[19](#cas14167-bib-0019){ref-type="ref"}

The largest study, which included 473 patients from the European Society for Blood and Marrow Transplantation (EBMT) Acute Leukemia Working Party, showed that post‐transplant TKI was associated with a lower relapse rate and better overall survival.[6](#cas14167-bib-0006){ref-type="ref"} However, this retrospective study included patients who did not receive TKI before HSCT and did not provide information on MRD status or the dose and timing of TKI. Consequently, it is unclear which patients derived this clinically relevant benefit. As a result of the particularly high relapse rate in patients with persistent positive‐MRD or recurrent MRD detection after HSCT,[20](#cas14167-bib-0020){ref-type="ref"}, [21](#cas14167-bib-0021){ref-type="ref"} giving immediate TKI is recommended in these patients.[19](#cas14167-bib-0019){ref-type="ref"} Meanwhile, the clinical benefit of giving prophylactic TKI before MRD detection is unclear. Suppression of tumor burden, not eradication, by giving TKI might be sufficient to achieve cure under a potent graft‐versus‐leukemia effect. In addition, because adverse events as a result of TKI after HSCT are common, the balance of risk and benefit of giving TKI after HSCT should be considered. Therefore, we conducted a nationwide retrospective study to evaluate whether TKI prophylaxis after allogenic HSCT in patients with negative‐MRD would reduce relapse and improve overall survival.

2. MATERIALS AND METHODS {#cas14167-sec-0002}
========================

2.1. Data source and patient selection {#cas14167-sec-0003}
--------------------------------------

Clinical data were obtained from the Transplant Registry Unified Management Program (TRUMP), which includes data from the Japan Society for Hematopoietic Cell Transplantation (JSHCT).[22](#cas14167-bib-0022){ref-type="ref"}, [23](#cas14167-bib-0023){ref-type="ref"}

This study included patients with Ph+ ALL aged more than 15 years who received TKI before HSCT and underwent their first allogenic HSCT between January 2001 and December 2016. Patients who did not achieve negative‐MRD at first‐time evaluation after HSCT were excluded. Cases of HSCT with peripheral blood from an unrelated donor were excluded as it is not allowed in Japan. This retrospective study was approved by the data management committee of TRUMP and by the Institutional Review Board of Saitama Medical Center, Jichi Medical University.

2.2. Definitions of negative‐MRD and treatment strategies {#cas14167-sec-0004}
---------------------------------------------------------

Minimal residual disease was determined by qualitative or real‐time quantitative PCR. In most laboratories, qualitative PCR and real‐time quantitative PCR were carried out based on previous reports,[24](#cas14167-bib-0024){ref-type="ref"}, [25](#cas14167-bib-0025){ref-type="ref"} and BCR‐ABL mRNA copy numbers normalized relative to the number of transcripts of GAPDH were converted to copies per microgram of RNA. The threshold for quantification was 50 copies per microgram of RNA. Below this threshold by real‐time quantitative PCR or an undetectable level by qualitative PCR was defined as negative‐MRD. MRD status at HSCT was evaluated within 30 days prior to HSCT. Only data on MRD at HSCT and first‐time evaluation after HSCT were available in this database.

Giving TKI within 180 days after HSCT in a patient who maintained negative‐MRD was defined as prophylactic TKI. Upon the detection of MRD, the attending doctors at each institution made a clinical decision about whether to apply further observation or a treatment intervention. The end of TKI prophylaxis was defined until death, hematological relapse or discontinuation of TKI.

2.3. Endpoints and statistical analysis {#cas14167-sec-0005}
---------------------------------------

Primary endpoint was hematological relapse and secondary endpoints were overall survival and the incidence of chronic graft‐versus‐host disease (GVHD). Cumulative incidences of hematological relapse and GVHD were calculated by Gray\'s method. Probability of overall survival was estimated by the Kaplan‐Meier method. Cox proportional hazards regression models were used to evaluate the impact of TKI prophylaxis and confounding variables. TKI prophylaxis, grade II‐IV acute GVHD, and chronic GVHD were treated as time‐dependent covariates. Impact of TKI prophylaxis was graphically illustrated using Simon‐Makuch plots.[26](#cas14167-bib-0026){ref-type="ref"} In subgroup analyses to determine the impact of TKI prophylaxis using imatinib or dasatinib, TKI prophylaxis using other than the target TKI were treated as censoring events.

The following variables were considered: the recipient\'s age at HSCT, recipient\'s gender (female vs male), performance status (0‐1 vs 2‐4), white blood cell count (WBC) at diagnosis (\<30 000/μL vs ≥30 000/μL), breakpoint (minor vs major), time from diagnosis to HSCT (\<180 days vs ≥180 days), donor source (human leukocyte antigen \[HLA\]‐matched related donor vs HLA‐mismatched related donor vs unrelated donor for bone marrow vs umbilical cord blood), conditioning intensity (myeloablative vs reduced‐intensity), GVHD prophylaxis (cyclosporine‐based vs tacrolimus‐based), use of in vivo T‐cell depletion, year of HSCT (2001‐2011 vs 2012‐2016), disease status at HSCT (negative‐MRD with CR vs positive‐MRD with CR vs active disease), grade II‐IV acute GVHD, chronic GVHD and TKI prophylaxis. Additional cytogenetic abnormalities were not considered as confounding variables.[27](#cas14167-bib-0027){ref-type="ref"} Acute and chronic GVHD were diagnosed by conventional criteria.[28](#cas14167-bib-0028){ref-type="ref"}, [29](#cas14167-bib-0029){ref-type="ref"} Intensity of the conditioning regimen was classified based on criteria from the Center for International Blood and Marrow Transplant Research.[30](#cas14167-bib-0030){ref-type="ref"}

Factors with a two‐sided *P* value of \<.15 in univariate analyses and the use of TKI prophylaxis were included in multivariate analyses. All *P* values were two‐sided and significance was set at .05. All statistical analyses were carried out with SAS (version 9.4) and EZR version 1.37,[31](#cas14167-bib-0031){ref-type="ref"} which is a graphical user interface for R (version 3.2.2). The analyses including time‐dependent covariates were completed with the use of PROC PHREG in SAS software.

3. RESULTS {#cas14167-sec-0006}
==========

3.1. Patient characteristics {#cas14167-sec-0007}
----------------------------

During the study period, 1149 patients with Ph+ ALL received their first allogenic HSCT. One‐hundred and sixty‐five patients whose MRD information early after HSCT was not available and 134 patients who did not achieve negative‐MRD after HSCT were excluded. Overall, we evaluated 850 patients who underwent their first allogenic HSCT and achieved negative‐MRD within 180 days after HSCT (Table [1](#cas14167-tbl-0001){ref-type="table"}). Median observation period of the survivors was 1539 days (range, 91‐5672 days) and the 4‐year overall survival rate was 72.1% (95% confidence interval \[CI\], 68.7%‐75.3%). Cumulative incidences of hematological relapse, grade II‐IV acute GVHD and chronic GVHD were 12.6% (95% CI, 10.3%‐15.0%), 43.2% (95% CI, 39.8%‐46.5%) and 39.5% (95% CI, 36.2%‐42.8%), respectively. In our cohort, 50 patients received TKI prophylaxis, and median time from HSCT to prophylaxis was 62.5 days (range, 21‐180 days). Imatinib (44%) and dasatinib (54%) were commonly given as TKI prophylaxis. Median observation period of the survivors who received TKI prophylaxis with imatinib and dasatinib was 2561 days (range, 605‐4796 days) and 1198 days (range, 309‐1949 days), respectively. Median mode doses of imatinib and dasatinib were 400 mg per day (range, 60‐600 mg per day) and 40 mg per day (range, 20‐100 mg per day), respectively. Median duration of giving prophylactic TKI was 175.5 days (range, 3‐3127 days). Of the 50 patients with TKI prophylaxis, six patients developed hematological relapse. Among these six patients, five patients continued TKI until hematological relapse, and one patient who received TKI prophylaxis between day + 56 and day + 146 ultimately developed hematological relapse at day + 462. Associations between patient characteristics and the cumulative incidence of TKI prophylaxis were evaluated using Cox proportional hazards regression models (Table [2](#cas14167-tbl-0002){ref-type="table"}). Multivariate analysis showed that prophylactic TKI was more frequently given during the late time periods of HSCT (hazard ratio \[HR\], 1.86; 95% CI, 1.02‐3.38; *P *=* *.042) or with positive‐MRD at HSCT (HR, 2.25; 95% CI, 1.21‐4.16; *P *=* *.010). There was a trend toward less frequent administration of TKI prophylaxis in patients who developed grade II‐IV acute GVHD (HR, 0.52; 95% CI, 0.27‐1.01; *P *=* *.055).

###### 

Characteristics of patients who underwent their first allogenic HSCT and achieved negative‐MRD within 180 days after HSCT

                                                               Disease status at HSCT                                     
  ------------------------------------------------------------ ------------------------ ---------------- ---------------- ---------------
  Median age at HSCT, y (range)                                46 (16‐71)               46 (16‐70)       46 (16‐71)       45.5 (16‐67)
  Recipient gender                                                                                                        
  Female                                                       367 (43.2)               259 (44.3)       64 (39.3)        16 (42.1)
  Male                                                         483 (56.8)               326 (55.7)       99 (60.7)        22 (57.9)
  Performance status                                                                                                      
  0‐1                                                          792 (93.2)               549 (93.8)       149 (91.4)       30 (78.9)
  2‐4                                                          52 (6.1)                 34 (5.8)         10 (6.1)         8 (21.1)
  Missing data                                                 6 (0.7)                  2 (0.3)          4 (2.5)          0 (0)
  WBC at diagnosis                                                                                                        
  \<30 000/μL                                                  473 (55.7)               339 (57.9)       75 (46.0)        17 (44.7)
  ≥30 000/μL                                                   363 (42.7)               236 (40.3)       87 (53.4)        18 (47.4)
  Missing data                                                 14 (1.7)                 10 (1.7)         1 (0.6)          3 (7.9)
  Breakpoint                                                                                                              
  Minor                                                        639 (75.2)               438 (74.9)       118 (72.4)       30 (78.9)
  Major                                                        169 (19.9)               114 (19.5)       41 (25.2)        6 (15.8)
  Both                                                         24 (2.8)                 19 (3.2)         2 (1.2)          2 (5.3)
  Missing data                                                 18 (2.1)                 14 (2.4)         2 (1.2)          0 (0)
  Time from diagnosis to HSCT                                                                                             
  \<180 d                                                      398 (46.8)               288 (49.2)       71 (43.6)        8 (21.1)
  ≥180 d                                                       451 (53.1)               296 (50.6)       92 (56.4)        30 (78.9)
  Missing data                                                 1 (0.1)                  1 (0.2)          0 (0)            0 (0)
  Donor source                                                                                                            
  HLA‐matched related                                          192 (22.6)               128 (21.9)       36 (22.1)        8 (21.1)
  HLA‐mismatched related                                       38 (4.5)                 16 (2.7)         13 (8.0)         6 (15.8)
  Unrelated, bone marrow                                       400 (47.1)               291 (49.7)       66 (40.5)        16 (42.1)
  Unrelated, cord blood                                        220 (25.9)               150 (25.6)       48 (29.4)        8 (21.1)
  Conditioning intensity                                                                                                  
  Myeloablative                                                610 (71.8)               425 (72.6)       118 (72.4)       23 (60.5)
  Reduced intensity                                            239 (28.1)               159 (27.2)       45 (27.6)        15 (39.5)
  Missing data                                                 1 (0.1)                  1 (0.2)          0 (0)            0 (0)
  GVHD prophylaxis                                                                                                        
  CSA‐based                                                    296 (34.8)               203 (34.7)       64 (39.3)        9 (23.7)
  TAC‐based                                                    540 (63.5)               369 (63.1)       98 (60.1)        29 (76.3)
  Missing data                                                 14 (1.7)                 13 (2.2)         1 (0.6)          0 (0)
  Use of in vivo T‐cell depletion                                                                                         
  No                                                           811 (95.4)               562 (96.1)       155 (95.1)       34 (89.5)
  Yes                                                          39 (4.6)                 23 (3.9)         8 (4.9)          4 (10.5)
  Year of HSCT                                                                                                            
  2001‐2011                                                    413 (48.6)               271 (46.3)       92 (56.4)        15 (39.5)
  2012‐2016                                                    437 (51.4)               314 (53.7)       71 (43.6)        23 (60.5)
  Disease status at HSCT                                                                                                  
  Negative‐MRD with CR                                         585 (68.8)                                                  
  CR1                                                          552 (94.4)                                                  
  CR2 or CR3                                                   33 (5.6)                                                    
  Positive‐MRD with CR                                         163 (19.2)                                                  
  CR1                                                          148 (90.8)                                                  
  CR2 or CR3                                                   15 (9.2)                                                    
  Active disease                                               38 (4.5)                                                    
  Missing data for MRD status at HSCT                          64 (7.5)                                                    
  Final use of TKI before HSCT                                                                                            
  Imatinib                                                     505 (59.4)               366 (62.6)       89 (54.6)        12 (31.6)
  Dasatinib                                                    340 (40.0)               216 (36.9)       73 (44.8)        25 (65.8)
  Nilotinib                                                    5 (0.6)                  3 (0.5)          1 (0.6)          1 (2.6)
  Median time from HSCT to prophylaxis, days (range)           62.5 (21‐180)            92 (21‐180)      49.5 (21‐161)    55 (42‐62)
  TKI prophylaxis                                                                                                         
  Imatinib                                                     22 (44.0)                17 (56.7)        4 (25.0)         1 (33.3)
  Dasatinib                                                    27 (54.0)                12 (40.0)        12 (75.0)        2 (66.7)
  Nilotinib                                                    1 (2.0)                  1 (3.3)          0 (0)            0 (0)
  Median dose of TKI prophylaxis, mg per day (range)                                                                      
  Imatinib                                                     400 (60‐600)             400 (60‐600)     400 (100‐600)    400 (400‐400)
  Dasatinib                                                    40 (20‐100)              40 (20‐50)       50 (20‐100)      35 (20‐50)
  Median duration of prophylactic TKI exposure, days (range)   175.5 (3‐3127)           105 (3‐2757)     288.5 (5‐3127)   44 (35‐220)
  Imatinib                                                     140 (3‐3127)             90 (3‐2757)      1978 (97‐3127)   35 (35‐35)
  Dasatinib                                                    187 (5‐802)              136.5 (12‐642)   227 (5‐802)      132 (44‐220)

Abbreviations: CR, complete remission; CSA, cyclosporine; GVHD, graft‐versus‐host disease; HLA, human leukocyte antigen; HSCT, hematopoietic stem cell transplantation; MRD, minimal residual disease; TAC, tacrolimus; TKI, tyrosine kinase inhibitor; WBC, white blood cell count.
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###### 

Associations between patient characteristics and TKI prophylaxis

                                                                  Univariate analysis   *P* value   Multivariate analysis   *P* value
  --------------------------------------------------------------- --------------------- ----------- ----------------------- -----------
  Age at HSCT                                                     1.01 (0.99‐1.03)      .503                                 
  Recipient gender                                                                                                          
  Female                                                          1                     Reference                            
  Male                                                            0.97 (0.56‐1.70)      .926                                 
  Performance status                                                                                                        
  0‐1                                                             1                     Reference                            
  2‐4                                                             1.79 (0.71‐4.50)      .218                                 
  WBC at diagnosis                                                                                                          
  \<30 000/μL                                                     1                     Reference                            
  ≥30 000/μL                                                      1.32 (0.76‐2.29)      .331                                 
  Breakpoint                                                                                                                
  Minor                                                           1                     Reference                            
  Major                                                           0.75 (0.40‐1.41)      .375                                 
  Time from diagnosis to HSCT                                                                                               
  \<180 d                                                         1                     Reference                            
  ≥180 d                                                          0.89 (0.51‐1.55)      .677                                 
  Donor source                                                                                                              
  HLA‐matched related                                             1                     Reference                            
  HLA‐mismatched related                                          1.20 (0.34‐4.19)      .781                                 
  Unrelated, bone marrow                                          0.67 (0.33‐1.37)      .272                                 
  Unrelated, cord blood                                           1.07 (0.52‐2.23)      .854                                 
  Conditioning intensity                                                                                                    
  Myeloablative                                                   1                     Reference                            
  Reduced intensity                                               1.00 (0.54‐1.85)      1.000                                
  GVHD prophylaxis                                                                                                          
  CSA‐based                                                       1                     Reference                            
  TAC‐based                                                       0.71 (0.40‐1.25)      .233                                 
  Use of in vivo T‐cell depletion                                                                                           
  No                                                              1                     Reference                            
  Yes                                                             0.84 (0.20‐3.44)      .803                                 
  Year of HSCT                                                                                                              
  2001‐2011                                                       1                     Reference   1                       Reference
  2012‐2016                                                       1.56 (0.88‐2.77)      .125        1.86 (1.02‐3.38)        .042
  Disease status at HSCT                                                                                                    
  Negative‐MRD with CR                                            1                     Reference   1                       Reference
  Positive‐MRD with CR                                            2.10 (1.14‐3.87)      .017        2.25 (1.21‐4.16)        .010
  Active disease                                                  1.69 (0.51‐5.54)      .389        1.69 (0.51‐5.56)        .388
  Grade II‐IV acute GVHD[a](#cas14167-note-0003){ref-type="fn"}   0.55 (0.29‐1.05)      .068        0.52 (0.27‐1.01)        .055
  Chronic GVHD[a](#cas14167-note-0003){ref-type="fn"}             0.95 (0.32‐2.82)      .930                                 

Abbreviations: CI, confidence interval; CR, complete remission; CSA, cyclosporine; GVHD, graft‐versus‐host disease; HLA, human leukocyte antigen; HSCT, hematopoietic stem cell transplantation; MRD, minimal residual disease; TAC, tacrolimus; TKI, tyrosine kinase inhibitor; WBC, white blood cell count.

Time‐dependent covariate.
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3.2. Impact of TKI prophylaxis on hematological relapse, overall survival and chronic GVHD {#cas14167-sec-0008}
------------------------------------------------------------------------------------------

Four‐year cumulative incidences of hematological relapse without TKI prophylaxis (n = 800) were 12.6% (95% CI, 10.2%‐15.1%). According to the univariate analysis regarding hematological relapse, WBC at diagnosis, donor source, conditioning intensity, and disease status at HSCT were considered the confounding variables (*P *\<* *.15). Multivariate analysis showed that disease status at HSCT was the sole independent risk factor for hematological relapse (HR, 3.58; 95% CI, 2.30‐5.57; *P *\<* *.001 for positive‐MRD with CR, and HR, 6.13; 95% CI, 3.12‐12.04; *P *\<* *.001 for active disease) (Table [3](#cas14167-tbl-0003){ref-type="table"}). TKI prophylaxis as a time‐dependent covariate did not significantly affect hematological relapse in a multivariate analysis (HR, 0.69; 95% CI, 0.30‐1.59; *P *=* *.384). A Simon‐Makuch plot was constructed to illustrate the effect of TKI prophylaxis on hematological relapse (Figure [1](#cas14167-fig-0001){ref-type="fig"}A).

###### 

Risk factors for hematological relapse and overall survival in univariate and multivariate analyses

                                                                  Hematological relapse   Overall survival                                                                                     
  --------------------------------------------------------------- ----------------------- ------------------ ------------------- ----------- ------------------ ----------- ------------------ -----------
  Age at HSCT                                                     1.01 (0.99‐1.02)        .274                                               1.03 (1.02‐1.04)   \<.001      1.03 (1.01‐1.04)   \<.001
  Recipient gender                                                                                                                                                                             
  Female                                                          1                       Reference                                          1                  Reference                       
  Male                                                            1.05 (0.71‐1.55)        .824                                               1.20 (0.92‐1.55)   .175                            
  Performance status                                                                                                                                                                           
  0‐1                                                             1                       Reference                                          1                  Reference   1                  Reference
  2‐4                                                             0.86 (0.35‐2.11)        .740                                               1.48 (0.91‐2.39)   .112        1.19 (0.72‐1.97)   .492
  WBC at diagnosis                                                                                                                                                                             
  \<30 000/μL                                                     1                       Reference          1                   Reference   1                  Reference   1                  Reference
  ≥30 000/μL                                                      1.46 (0.99‐2.15)        .059               1.40 (0.92‐2.12)    .114        1.22 (0.94‐1.58)   .130        1.25 (0.95‐1.63)   .112
  Breakpoint                                                                                                                                                                                   
  Minor                                                           1                       Reference                                          1                  Reference                       
  Major                                                           1.12 (0.69‐1.81)        .642                                               0.99 (0.73‐1.35)   .959                            
  Time from diagnosis to HSCT                                                                                                                                                                  
  \<180 d                                                         1                       Reference                                          1                  Reference   1                  Reference
  ≥180 d                                                          1.30 (0.88‐1.93)        .184                                               1.53 (1.17‐1.99)   .002        1.27 (0.94‐1.70)   .115
  Donor source                                                                                                                                                                                 
  HLA‐matched related                                             1                       Reference          1                   Reference   1                  Reference   1                  Reference
  HLA‐mismatched related                                          1.99 (0.89‐4.46)        .093               1.20 (0.49‐2.95)    .694        1.60 (0.88‐2.90)   .122        1.15 (0.60‐2.23)   .672
  Unrelated, bone marrow                                          0.94 (0.56‐1.56)        .797               1.08 (0.63‐1.86)    .779        1.28 (0.92‐1.78)   .150        1.20 (0.83‐1.75)   .329
  Unrelated, cord blood                                           1.22 (0.71‐2.10)        .476               1.24 (0.69‐2.22)    .481        1.07 (0.72‐1.57)   .749        0.96 (0.63‐1.47)   .852
  Conditioning intensity                                                                                                                                                                       
  Myeloablative                                                   1                       Reference          1                   Reference   1                  Reference   1                  Reference
  Reduced intensity                                               1.57 (1.05‐2.36)        .028               1.44 (0.92‐2.26)    .108        1.37 (1.04‐1.80)   .024        1.07 (0.75‐1.52)   .709
  GVHD prophylaxis                                                                                                                                                                             
  CSA‐based                                                       1                       Reference                                          1                  Reference                       
  TAC‐based                                                       0.92 (0.62‐1.38)        .699                                               1.17 (0.89‐1.53)   .254                            
  Use of in vivo T‐cell depletion                                                                                                                                                              
  No                                                              1                       Reference                                          1                  Reference                       
  Yes                                                             1.40 (0.61‐3.19)        .430                                               0.94 (0.48‐1.83)   .850                            
  Year of HSCT                                                                                                                                                                                 
  2001‐2011                                                       1                       Reference                                          1                  Reference                       
  2012‐2016                                                       1.11 (0.75‐1.66)        .606                                               1.05 (0.80‐1.37)   .741                            
  Disease status at HSCT                                                                                                                                                                       
  Negative‐MRD with CR                                            1                       Reference          1                   Reference   1                  Reference   1                  Reference
  Positive‐MRD with CR                                            3.83 (2.49‐5.89)        \<.001             3.58 (2.30‐5.57)    \<.001      1.95 (1.46‐2.60)   \<.001      1.96 (1.45‐2.64)   \<.001
  Active disease                                                  7.00 (3.75‐13.06)       \<.001             6.13 (3.12‐12.04)   \<.001      3.03 (1.84‐4.96)   \<.001      2.59 (1.52‐4.41)   .001
  Grade II‐IV acute GVHD[a](#cas14167-note-0005){ref-type="fn"}   0.93 (0.63‐1.38)        .717                                               1.89 (1.46‐2.44)   \<.001      1.92 (1.46‐2.53)   \<.001
  Chronic GVHD[a](#cas14167-note-0005){ref-type="fn"}             0.81 (0.52‐1.25)        .337                                               1.22 (0.94‐1.60)   .135        1.19 (0.90‐1.58)   .232
  TKI prophylaxis[a](#cas14167-note-0005){ref-type="fn"}                                                                                                                                       
  No                                                              1                       Reference          1                   Reference   1                  Reference   1                  Reference
  Yes                                                             0.99 (0.43‐2.26)        .983               0.69 (0.30‐1.59)    .384        0.90 (0.51‐1.57)   .708        0.76 (0.42‐1.37)   .367

Abbreviations: CI, confidence interval; CR, complete remission; CSA, cyclosporine; GVHD, graft‐versus‐host disease; HLA, human leukocyte antigen; HSCT, hematopoietic stem cell transplantation; MRD, minimal residual disease; TAC, tacrolimus; TKI, tyrosine kinase inhibitor; WBC, white blood cell count.

Time‐dependent covariate.
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![Simon‐Makuch plot for the effect of tyrosine kinase inhibitor prophylaxis on the cumulative incidences of (A) hematological relapse and (B) overall survival, illustrated with a landmark at day 62.5, the median time from hematopoietic stem cell transplantation to prophylaxis](CAS-110-3255-g001){#cas14167-fig-0001}

We next evaluated the effect of TKI prophylaxis on overall survival. Univariate analysis showed that age at HSCT, performance status, WBC at diagnosis, time from diagnosis to HSCT, donor source, conditioning intensity, disease status at HSCT, grade II‐IV acute GVHD, and chronic GVHD were associated with poor overall survival with at least borderline significance (*P *\<* *.15). In the multivariate analysis, age at HSCT (HR, 1.03; 95% CI 1.01‐1.04; *P *\<* *.001), disease status at HSCT (HR, 1.96; 95% CI, 1.45‐2.64; *P *\<* *.001 for positive‐MRD with CR, and HR, 2.59; 95% CI, 1.52‐4.41; *P *=* *.001 for active disease), and grade II‐IV acute GVHD (HR, 1.92; 95% CI, 1.46‐2.53; *P *\<* *.001) were significantly associated with inferior overall survival. TKI prophylaxis was not significantly associated with superior overall survival in a multivariate analysis (HR, 0.76; 95% CI, 0.42‐1.37; *P *=* *.367) (Table [3](#cas14167-tbl-0003){ref-type="table"}). Effect of TKI prophylaxis on overall survival was illustrated using the Simon‐Makuch method (Figure [1](#cas14167-fig-0001){ref-type="fig"}B).

We also determined the association between the incidence of chronic GVHD and TKI prophylaxis. In the multivariate analysis, WBC at diagnosis (HR, 1.36; 95% CI, 1.10‐1.68; *P *=* *.004), unrelated cord blood transplantation (HR, 0.70; 95% CI, 0.52‐0.95; *P *=* *.022), reduced conditioning intensity (HR, 0.77; 95% CI, 0.60‐0.99; *P *=* *.042) and grade II‐IV acute GVHD (HR, 1.36; 95% CI, 1.10‐1.68; *P *=* *.004) were significantly associated with the incidence of chronic GVHD (Table [S1](#cas14167-sup-0002){ref-type="supplementary-material"}). The incidence of chronic GVHD was not significantly associated with TKI prophylaxis in the multivariate analysis (HR, 0.82; 95% CI, 0.49‐1.35; *P *=* *.428).

3.3. Impact of TKI prophylaxis in patients with negative‐MRD or positive‐MRD at HSCT {#cas14167-sec-0009}
------------------------------------------------------------------------------------

Disease status at HSCT was significantly associated with hematological relapse and overall mortality even if patients achieved negative‐MRD early after HSCT (*P *\<* *.001, respectively) (Figure [2](#cas14167-fig-0002){ref-type="fig"}). Cumulative incidence of hematological relapse at 4 years was 7.8% (95% CI, 5.7%‐10.4%) for negative‐MRD with CR at HSCT, 24.4% (95% CI, 17.8%‐31.5%) for positive‐MRD with CR at HSCT, and 36.3% (95% CI, 20.6%‐52.2%) for active disease at HSCT. Probability of overall survival at 4 years was 76.5% (95% CI, 72.5%‐80.0%) for negative‐MRD with CR at HSCT, 62.2% (95% CI, 53.7%‐69.7%) for positive‐MRD with CR at HSCT, and 40.2% (95% CI, 20.7%‐58.9%) for active disease at HSCT. These results encouraged us to carry out post hoc analyses to identify each disease status at HSCT for which TKI prophylaxis may be beneficial. Cases of active disease at HSCT were not evaluated because of the limited number of patients.

![Cumulative incidences of (A) hematological relapse and (B) overall survival according to disease status at hematopoietic stem cell transplantation. HSCT, hematopoietic stem cell transplantation; MRD, minimal residual disease](CAS-110-3255-g002){#cas14167-fig-0002}

Median time from HSCT to prophylaxis for negative‐MRD and positive‐MRD with first CR (CR1) was 90 days (range, 21‐166 days) and 49 days (range, 21‐161 days), respectively. Effect of TKI prophylaxis on hematological relapse for negative‐MRD and positive‐MRD with CR1 were illustrated using the Simon‐Makuch method (Figure [S1](#cas14167-sup-0002){ref-type="supplementary-material"}). Multivariate analysis showed that none of the covariates was associated with hematological relapse in patients with negative‐MRD and positive‐MRD with CR1 (Table [S2](#cas14167-sup-0002){ref-type="supplementary-material"}). Overall survival was also analyzed in the same subgroups. Overall, TKI prophylaxis had no significant impact on hematological relapse or overall mortality among patients with negative‐MRD and positive‐MRD with CR1 (Table [S3](#cas14167-sup-0002){ref-type="supplementary-material"}).

3.4. Impact of TKI choices {#cas14167-sec-0010}
--------------------------

We also assessed the impact of TKI prophylaxis limited to imatinib or dasatinib. In the multivariate analyses, TKI prophylaxis with imatinib did not affect hematological relapse (HR, 1.29; 95% CI, 0.47‐3.56; *P *=* *.626) and overall mortality (HR, 0.96; 95% CI, 0.45‐2.05; *P *=* *.906) (Table [S4](#cas14167-sup-0002){ref-type="supplementary-material"}). In a multivariate analysis limited to dasatinib, disease status at HSCT was the only risk factor for hematological relapse (HR, 3.79; 95% CI, 2.41‐5.96; *P *\<* *.001 for positive‐MRD with CR, and HR, 6.85; 95% CI, 3.41‐13.77; *P *\<* *.001 for active disease) (Table [S5](#cas14167-sup-0002){ref-type="supplementary-material"}). TKI prophylaxis with dasatinib might be associated with a decreased risk of hematological relapse, but was not statistically significant (HR, 0.34; 95% CI, 0.08‐1.42; *P *=* *.140). For overall mortality, HR was 0.59 in patients with TKI prophylaxis using dasatinib (95% CI, 0.24‐1.45; *P *=* *.253).

4. DISCUSSION {#cas14167-sec-0011}
=============

We showed that TKI prophylaxis was not associated with a lower relapse rate or overall mortality in the whole cohort of this study. Pfeifer et al[32](#cas14167-bib-0032){ref-type="ref"} conducted a randomized trial that compared prophylactic and MRD‐triggered imatinib groups who achieved negative‐MRD early after HSCT. This trial, which included 54 patients, showed that the probabilities of relapse‐free survival and overall survival did not significantly differ, which is consistent with our results. Interestingly, the 5‐year overall survival rates in these groups (80% for prophylactic and 74.5% for MRD‐triggered) were remarkably high, as in our study (72.1% 4‐year overall survival rate). Another study also showed that the 2‐year overall survival rates in patients who achieved negative‐MRD and persistent MRD early after HSCT were 80% and 13%, respectively.[21](#cas14167-bib-0021){ref-type="ref"} These results confirm that achieving negative‐MRD after HSCT is associated with a favorable survival outcome due to a lower relapse rate. The lack of benefit with TKI prophylaxis might be attributed to the outstanding outcome in these populations.

Importantly, we identified that disease status at HSCT was a powerful risk factor for hematological relapse even if patients achieved negative‐MRD after HSCT. However, TKI prophylaxis was not associated with a decreased incidence of hematological relapse even in the subgroup analysis limited to positive‐MRD with CR1 at HSCT. In contrast, TKI prophylaxis using dasatinib might reduce hematological relapse in multivariate analysis. As this analysis limited to dasatinib might lack the power to detect a meaningful difference because of the small sample size, this subgroup analysis needs to be interpreted with care. Several studies have shown that BCR‐ABL1 kinase domain mutations are the major cause of relapse in Ph+ ALL.[7](#cas14167-bib-0007){ref-type="ref"}, [8](#cas14167-bib-0008){ref-type="ref"} Rousselot et al[9](#cas14167-bib-0009){ref-type="ref"} reported that 10 of 43 patients (23%) at diagnosis had T315I mutations and eight of these 10 ultimately developed relapse despite undetectable MRD during CR. Another study suggested that tumor strains at post‐transplant relapse had the same BCR‐ABL1 kinase domain mutations before HSCT.[33](#cas14167-bib-0033){ref-type="ref"} These findings suggest that disease status at HSCT may be associated with the presence of BCR‐ABL1 kinase domain mutations. Therefore, patients with positive‐MRD or active disease at HSCT require BCR‐ABL1 kinase domain mutation analysis and close monitoring after HSCT, if possible. Considering the efficacy for BCR‐ABL1 kinase domain mutation and the higher potency of second‐ or third‐generation TKI, further investigation using new‐generation TKI based on MRD status and BCR‐ABL1 kinase domain mutation analysis is warranted.

Chronic GVHD is a well‐recognized factor that influences relapse.[34](#cas14167-bib-0034){ref-type="ref"} Several studies have reported TKI as a treatment option for steroid‐refractory chronic GVHD[35](#cas14167-bib-0035){ref-type="ref"}, [36](#cas14167-bib-0036){ref-type="ref"} and TKI may reduce the incidence and severity of chronic GVHD.[37](#cas14167-bib-0037){ref-type="ref"} Nevertheless, we did not observe a significant association between TKI prophylaxis and the incidence of chronic GVHD. Meanwhile, because parameters that reflect the severity of chronic GVHD such as National Institutes of Health severity scoring were not available in our database, the influence of TKI prophylaxis on the severity of chronic GVHD could not be evaluated. Further studies are required to confirm these results.

The dose, duration, and tolerability of TKI after HSCT are important topics. Side‐effects of TKI such as gastrointestinal or hematological toxicities are common, especially after HSCT, and these adverse events often result in discontinuation or dose‐reduction of TKI.[38](#cas14167-bib-0038){ref-type="ref"}, [39](#cas14167-bib-0039){ref-type="ref"} In the prospective trial by Pfeifer et al,[32](#cas14167-bib-0032){ref-type="ref"} although criteria for starting imatinib included sufficient hematological recovery, adequate organ function, and absence of uncontrolled GVHD, approximately 70% of patients discontinued imatinib prematurely and required dose reduction. Other studies also showed that dasatinib and nilotinib required dose reduction because of intolerance.[14](#cas14167-bib-0014){ref-type="ref"}, [40](#cas14167-bib-0040){ref-type="ref"} In our cohort, the median dose (400 mg with imatinib and 40 mg with dasatinib), duration of TKI exposure (175.5 days), and time from HSCT to TKI prophylaxis (62.5 days) were comparable to those in previous prospective studies.[14](#cas14167-bib-0014){ref-type="ref"}, [32](#cas14167-bib-0032){ref-type="ref"} One of the strengths of our study was that information regarding dose, duration and onset of TKI administration were available, whereas the reasons for discontinuation or dose modification of TKI were uncertain. As the frequency of TKI prophylaxis tended to be lower in patients with acute GVHD in our analysis, we need to take into account a possible selection bias by the attending doctors regarding the administration of TKI even after adjusting for other confounding factors, such as GVHD and MRD status at HSCT.

The present study has other limitations. First, the second or subsequent MRD status after HSCT, and detailed information about treatment interventions after MRD detection were not available in our database. However, the impact of TKI given as prophylaxis before MRD detection could be evaluated despite the lack of this information. Second, the MRD detection method was not unified and centralized in this nationwide retrospective study. Therefore, a minimal sensitivity of MRD detection had variation to some extent. Third, the number of patients who were given TKI prophylaxis was not large, because the Japanese guidelines do not provide any recommendations about TKI prophylaxis after HSCT. It is presumed that TKI prophylaxis was carried out at the discretion of the attending physician. This was an exploratory retrospective study, and thus we did not calculate the sample size before collecting the samples. Based on 12.6% risk of hematological relapse without TKI prophylaxis in our cohort, which was lower than expected, large sample size with TKI prophylaxis might be needed to detect the impact of TKI prophylaxis with a statistically significant difference. This factor, along with the retrospective nature of the present study, requires that the current results be interpreted with caution. Because of the extraordinarily low risk of hematological relapse without TKI prophylaxis, TKI prophylaxis might be applied in selected patients who are more likely to relapse. Further studies using new‐generation TKI for high‐risk patients stratified by MRD status and BCR‐ABL1 kinase domain mutation analysis will be needed.

In conclusion, disease status at HSCT was a significant risk factor for hematological relapse even in patients who achieved negative‐MRD after HSCT. We failed to find a beneficial effect of TKI prophylaxis on hematological relapse or overall mortality despite MRD positivity at HSCT. In a subgroup analysis, TKI prophylaxis using dasatinib might be related to a lower frequency of hematological relapse. Given the lack of a large study that determined the effect of TKI prophylaxis, we believe this study provides an important insight for TKI use after HSCT in daily practice and for future studies.
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